TCDA News and Press, Tricida Inc. From 02/25/21

Tricida (TCDA) has plunged ~24.6% in the post-market after announcing an appeal denied letter received from the Office of New Drugs (OND) of the FDA in response to its Formal Dispute Resolution Request ("FDRR") submitted in December 2020.The FDRR related to whether the size and dura...

Tricida (TCDA): Q4 GAAP EPS of -$1.09.As of December 31, 2020, cash, cash equivalents and investments were $332.3 million.Press Release For further details see: Tricida reports Q4 results

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to trea...

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabol...

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2020 financial results after the close of market on Thursday, February 25, 2021. Tricida will host a conference call and webca...

BOSTON, MA / ACCESSWIRE / January 6, 2021 / Nationally-recognized securities law firm Block & Leviton LLP ( www.blockleviton.com ) announces that a lawsuit for violation of the federal securities laws has been filed against Tricida, Inc. (NASDAQ:TCDA) and certain of its executives. On J...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 11:50 am PT / 2:50 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Fou...

Tricida (TCDA) drops 14% after-hours after announcing key updates on veverimer’s development program, regulatory status and patent protection. The company has revised the protocol for its VALOR-CKD outcome trial. The trial protocol previously had an adaptive design and includ...

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to trea...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to trea...